So basically you are saying not to expect more than 10cps...

First 59 Last

Share
Profile

Follow
BazTokyo

1,989 Posts.

120

19/09/17

15:18

Post #: 27319185
Share

Originally posted by Pman ↑

Not expecting massive volumes (depending on what that means).

Sk2 under my analysis shows the top 6 products sell about 3 to 4 million units.
I expect about 1m units to be sold per product annually as they are not integrated. (does not include the wand)
The more products the more revenue

Olay though has more volume has lower royalty and should be able to deliver similar total royalties.

so for simplicity sake 1 product equals 1m per year. Sure the volume drops in following years but that is more than offset by more and more products.

5 to 6 million justifies a 4 to 6c share price. We are in a hairs width with 4 products and cash positive. As each product comes on line the revenue falls to the bottom line. Every million after that will justify 2c to the share price under current expenditure.

So given they can spit out 4 products in one year with no integrated products yet, 2nd platform which in my view will be a rehash of smarter products there is a lot of quick wins to come. For me once we get a integrated lid to the best sellers you are talking 3m+ unit sales not just 1m, this is the money product for me and when the shareprice will see 5c increase justification above its current position.

Time will tell how close my calcs will be and why I stay invested even though current events.

Expand

So basically you are saying not to expect more than 10cps meaning all the hype from the board and other holders is nonsense?

OBJ Price at posting: 4.4¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

PL3

Patagonia looks to raise $2.15M for South American exploration and development

There are more pages in this discussion • 31 more messages in this thread...

First 59 Last

Add WFL (ASX) to my watchlist

(20min delay)
Last 0.3¢		Change 0.000(0.00%)		Mkt cap ! $1.478M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

So basically you are saying not to expect more than 10cps...

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Featured News

So basically you are saying not to expect more than 10cps...

Top Stories

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Featured News